Terms: = Leukemia AND SETD2, ENSG00000181555, 29072
42 results:
1. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
[TBL] [Abstract] [Full Text] [Related]
2. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
3. Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Gaillard JB; Chapiro E; Daudignon A; Nadal N; Penther D; Chauzeix J; Nguyen-Khac F; Veronese L; Lefebvre C
Curr Res Transl Med; 2023; 71(4):103428. PubMed ID: 38016421
[TBL] [Abstract] [Full Text] [Related]
4.
Contreras Yametti GP; Robbins G; Chowdhury A; Narang S; Ostrow TH; Kilberg H; Greenberg J; Kramer L; Raetz E; Tsirigos A; Evensen NA; Carroll WL
Leuk Lymphoma; 2024 Jan; 65(1):78-90. PubMed ID: 37874744
[TBL] [Abstract] [Full Text] [Related]
5. New insights into the clinical characteristics of setd2-mutated acute myeloid leukaemia.
Zhang X; Wang Z; Sun J; Liu L; Qin J; Huang A; Yang M; Lou Y; Tang G; Mao L; Qian J; Wei J; Mai W; Meng H; Yang J; Tong H; Wang J; Yu W; Ni X; Jin J
Br J Haematol; 2023 Jul; 202(1):111-115. PubMed ID: 37038274
[TBL] [Abstract] [Full Text] [Related]
6. Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia.
Vráblová L; Divoký V; Kořalková P; Poláková KM; Kriegová E; Janská R; Grohmann J; Holzerová M; Papajík T; Faber E
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768374
[TBL] [Abstract] [Full Text] [Related]
7. setd2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients.
Liu H
Hematology; 2023 Dec; 28(1):2161194. PubMed ID: 36607144
[TBL] [Abstract] [Full Text] [Related]
8. Case report: Chronic lymphocytic leukemia/small lymphocytic lymphoma and monomorphic epitheliotropic intestinal T-cell lymphoma: A composite lymphoma.
Zhang B; Zhang Y; Li Q; Jiang Q; Chu W; Gong H; Li R; Ji H
Pathol Oncol Res; 2022; 28():1610653. PubMed ID: 36567979
[No Abstract] [Full Text] [Related]
9. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract] [Full Text] [Related]
10. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Wong J; Gruber E; Maher B; Waltham M; Sabouri-Thompson Z; Jong I; Luong Q; Levy S; Kumar B; Brasacchio D; Jia W; So J; Skinner H; Lewis A; Hogg SJ; Vervoort S; DiCorleto C; Uhe M; Gamgee J; Opat S; Gregory GP; Polekhina G; Reynolds J; Hawkes EA; Kailainathan G; Gasiorowski R; Kats LM; Shortt J
Leukemia; 2022 Jun; 36(6):1654-1665. PubMed ID: 35459873
[TBL] [Abstract] [Full Text] [Related]
11. Discovery of a Non-Nucleoside setd2 Methyltransferase Inhibitor against Acute Myeloid leukemia.
Bajusz D; Bognár Z; Ebner J; Grebien F; Keserű GM
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576219
[TBL] [Abstract] [Full Text] [Related]
12. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract] [Full Text] [Related]
13. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (setd2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract] [Full Text] [Related]
14. Intra-heterogeneity in transcription and chemoresistant property of leukemia-initiating cells in murine setd2
Song J; Du L; Liu P; Wang F; Zhang B; Xie Y; Lu J; Jin Y; Zhou Y; Lv G; Zhang J; Chen S; Chen Z; Sun X; Zhang Y; Huang Q
Cancer Commun (Lond); 2021 Sep; 41(9):867-888. PubMed ID: 34196511
[TBL] [Abstract] [Full Text] [Related]
15. The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.
Jiang S; Fan Y; Fang Y; Hou C; Chen J; Cen J; Qiu H; Chen S; Xu Y; Wu D
Bone Marrow Transplant; 2021 Feb; 56(2):470-480. PubMed ID: 32892217
[TBL] [Abstract] [Full Text] [Related]
16. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.
Bornhauser B; Cario G; Rinaldi A; Risch T; Rodriguez Martinez V; Schütte M; Warnatz HJ; Scheidegger N; Mirkowska P; Temperli M; Möller C; Schumich A; Dworzak M; Attarbaschi A; Brüggemann M; Ritgen M; Mejstrikova E; Hofmann A; Buldini B; Scarparo P; Basso G; Maglia O; Gaipa G; Skoblyn TL; Te Kronnie G; Vendramini E; Panzer-Grümayer R; Barz MJ; Marovca B; Hauri-Hohl M; Niggli F; Eckert C; Schrappe M; Stanulla M; Zimmermann M; Wollscheid B; Yaspo ML; Bourquin JP
Blood Adv; 2020 Sep; 4(17):4052-4064. PubMed ID: 32853382
[TBL] [Abstract] [Full Text] [Related]
17. setd2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract] [Full Text] [Related]
18. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
Chapiro E; Pramil E; Diop M; Roos-Weil D; Dillard C; Gabillaud C; Maloum K; Settegrana C; Baseggio L; Lesesve JF; Yon M; Jondreville L; Lesty C; Davi F; Le Garff-Tavernier M; Droin N; Dessen P; Algrin C; Leblond V; Gabarre J; Bouzy S; Eclache V; Gaillard B; Callet-Bauchu E; Muller M; Lefebvre C; Nadal N; Ittel A; Struski S; Collonge-Rame MA; Quilichini B; Fert-Ferrer S; Auger N; Radford-Weiss I; Wagner L; Scheinost S; Zenz T; Susin SA; Bernard OA; Nguyen-Khac F; ;
Blood; 2019 Nov; 134(21):1821-1831. PubMed ID: 31527074
[TBL] [Abstract] [Full Text] [Related]
19. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
20. Downregulation of the histone methyltransferase setd2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract] [Full Text] [Related]
[Next]
